Saracatinib (AZD0530)

Name: Saracatinib (AZD0530)
Brand: Selleck Chemicals
SKU: S1006
Rating: 5 (231 reviews)

For research use only.

Catalog No.S1006

231 publications

Saracatinib (AZD0530) Chemical Structure

CAS No. 379231-04-6

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Selleck's Saracatinib (AZD0530) has been cited by 231 publications

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(1):35-49

PubMed: 29249464 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Int J Cancer, 2021, 10.1002/ijc.33606

PubMed: 33890294 ( click the link to review the publication )

Oncogene, 2021, 40(14):2567-2580

PubMed: 33686238 ( click the link to review the publication )

FASEB J, 2021, 35(5):e21598

PubMed: 33871068 ( click the link to review the publication )

J Mol Cell Cardiol, 2021, S0022-2828(21)00134-6

PubMed: 34216608 ( click the link to review the publication )

Neurobiol Dis, 2021, 156:105410

PubMed: 34087381 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):25

PubMed: 33677467 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

BMC Cancer, 2021, 21(1):923

PubMed: 34399705 ( click the link to review the publication )

J Ovarian Res, 2021, 14(1):55

PubMed: 33888137 ( click the link to review the publication )

Arch Virol, 2021, 166(5):1433-1438

PubMed: 33683474 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Life Sci Alliance, 2021, 4(4)e202000832

PubMed: 33574034 ( click the link to review the publication )

Am J Clin Exp Urol, 2021, 9(4):350-366

PubMed: 34541033 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107796

PubMed: 32579923 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):4235-4249e6

PubMed: 32209481 ( click the link to review the publication )
Cell Rep, 2020, 33(7):108398

PubMed: 33207193 ( click the link to review the publication )

Sci Signal, 2020, 13(650)eaba5754

PubMed: 32963013 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):148

PubMed: 32746865 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

J Neurosci, 2020, 40(34):6522-6535

PubMed: 32690613 ( click the link to review the publication )

Cell Death Dis, 2020, 12;11(2):118

PubMed: 32051399 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

PLoS Genet, 2020, 16(3):e1008694

PubMed: 32196488 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):311-320

PubMed: 31832986 ( click the link to review the publication )

J Immunol, 2020, 205(7):1953-1961

PubMed: 32848033 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

Front Oncol, 2020, 3;10:442

PubMed: 32346533 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 9;10(1):4355

PubMed: 32152351 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00444.2019

PubMed: 33325804 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.012957

PubMed: 32934005 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2139-2151

PubMed: 32210580 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0224952

PubMed: 32692785 ( click the link to review the publication )

Neoplasia, 2020, 22(3):129-141

PubMed: 31981897 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):296

PubMed: 30655532 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4349

PubMed: 31554791 ( click the link to review the publication )

J Exp Med, 2019, 216(4):807-830

PubMed: 30819724 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(5):1639-1649

PubMed: 30504425 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3060-3076

PubMed: 31308216 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1311-1322.e5

PubMed: 31665642 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Mol Metab, 2019, 28:36-47

PubMed: 31327757 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0608-1

PubMed: 31649319 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2135-2145

PubMed: 31484705 ( click the link to review the publication )

J Immunol, 2019, 203(11):2990-2999

PubMed: 31619538 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2019, 316(3):C377-C392

PubMed: 30566391 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Dev Comp Immunol, 2019, 96:1-8

PubMed: 30822451 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1911-1917

PubMed: 30628679 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3625-3632

PubMed: 31485668 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(4)e201900425

PubMed: 31331982 ( click the link to review the publication )

Commun Biol, 2019, 2:156

PubMed: 31098401 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2068

PubMed: 29802342 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4259

PubMed: 30323235 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 78(4):985-1002.

PubMed: 29279356 ( click the link to review the publication )

Cancer Res, 2018, 78(22):6497-6508

PubMed: 30262461 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(21):2817-2836

PubMed: 29511352 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):887

PubMed: 30166523 ( click the link to review the publication )

FASEB J, 2018, 32(6):3033-3046

PubMed: 29401603 ( click the link to review the publication )

Neurobiol Dis, 2018, 110:102-121

PubMed: 29197620 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )
Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Metallomics, 2018, 10(8):1141-1159

PubMed: 30066004 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Exp Cell Res, 2018, 364(2):208-216

PubMed: 29427623 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

Cancer Med, 2018, 7(2):408-419

PubMed: 29318780 ( click the link to review the publication )

Cancer Med, 2018, 7(3):820-830

PubMed: 29383859 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Viruses, 2018, 10(6)

PubMed: 29795047 ( click the link to review the publication )

Tumour Biol, 2018, 40(8):1010428318794217

PubMed: 30124118 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )
Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cell Rep, 2017, 20(12):2775-2783

PubMed: 28930674 ( click the link to review the publication )

Cell Rep, 2017, 20(4):999-1015

PubMed: 28746882 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )

Cell Rep, 2017, 18(3):804-815

PubMed: 28099856 ( click the link to review the publication )

Sci Signal, 2017, 10(460)

PubMed: 28049762 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

J Virol, 2017, 91(21)

PubMed: 28814523 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

J Cancer, 2017, 8(11):1943-1951

PubMed: 28819393 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Leuk Res, 2017, 61:44-52

PubMed: 28888102 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Cancer Genet, 2017, 216-217:128-141

PubMed: 29025587 ( click the link to review the publication )

Biotechnol J, 2017, 12(10)

PubMed: 28786556 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103014-103031

PubMed: 29262541 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83872-83889

PubMed: 29137389 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )
Oncotarget, 2017, 8(61-:103014-103031

PubMed: 29262541 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Sci Transl Med, 2016, 8(354):354ra114

PubMed: 27582059 ( click the link to review the publication )

Theranostics, 2016, 6(4):594-609

PubMed: 26941850 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27216177 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra97

PubMed: 27703030 ( click the link to review the publication )

Brain Behav Immun, 2016, 55:236-248

PubMed: 26721416 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2572

PubMed: 28032865 ( click the link to review the publication )

PLoS Genet, 2016, 12(3):e1005931

PubMed: 26978032 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(9):2198-208

PubMed: 27256378 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Toxicology, 2016, 370:94-105

PubMed: 27693619 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(3):563-570

PubMed: 27666484 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27285768 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Sci Signal, 2015, 8(400):ra106

PubMed: 26508788 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2238-48

PubMed: 26208525 ( click the link to review the publication )
Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):377-88

PubMed: 25306394 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(12):2687-96

PubMed: 26390252 ( click the link to review the publication )

FEBS J, 2015, 10.1111/febs.13314

PubMed: 25940608 ( click the link to review the publication )

Biochem J, 2015, 468(3):495-506

PubMed: 25846210 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Pancreas, 2015, 44(1):152-7

PubMed: 25222135 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142219

PubMed: 26556238 ( click the link to review the publication )

Mol Cell Biochem, 2015, 407(1-2):197-207

PubMed: 26045172 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Nature, 2015, 519(7541):57-62

PubMed: 25731159 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29991-30005

PubMed: 26358373 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9476-87

PubMed: 25823815 ( click the link to review the publication )

Neurotherapeutics, 2015, 12(1):132-42

PubMed: 25549849 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25897-916

PubMed: 26317790 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(5):401-14

PubMed: 24705551 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3003-15

PubMed: 24911146 ( click the link to review the publication )
Cancer Res, 2014, 74(17):4762-71

PubMed: 25023728 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-38

PubMed: 24482380 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

J Chem Inf Model, 2014, 54(3):881-93

PubMed: 24490903 ( click the link to review the publication )

Ultrasound Med Biol, 2014, 40(6):1177-86

PubMed: 24612644 ( click the link to review the publication )

Placenta, 2014, 35(10):824-30

PubMed: 25108485 ( click the link to review the publication )

Oncotarget, 2014, 6(3)

PubMed: 25596741 ( click the link to review the publication )

University of Manche, 2014, aus Landshut

PubMed: ( click the link to review the publication )

J Neurooncol, 2014, 120(1):33-41

PubMed: 25048528 ( click the link to review the publication )

Oncotarget, 2014, 5(19):8853-68

PubMed: 25326682 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Pac Symp Biocomput, 2014, 2014:125-35

PubMed: 24297540 ( click the link to review the publication )

Dissertation zur Erlangung des Doktorgrades, 2014,

PubMed: ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Cell Biol, 2013, 15(4):395-405

PubMed: 23455479 ( click the link to review the publication )

Blood, 2013, 122(7):1203-13

PubMed: 23836556 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

Int J Cancer, 2013, 132(1):224-35

PubMed: 22623106 ( click the link to review the publication )

Breast Cancer Res, 2013,

PubMed: 24044505 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e915

PubMed: 24201814 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )
J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2013, 1829(10):1147-59

PubMed: 23948603 ( click the link to review the publication )

Mol Carcinog, 2013, 10.1002/mc.22092

PubMed: 24127286 ( click the link to review the publication )

PLoS One, 2013, 8(4):e60889

PubMed: 23593342 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Res, 2011, 71(24):7547-57

PubMed: 21994334 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(3):249-58

PubMed: 21296861 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Mol Endocrinol, 2010, 24(6):1151-64

PubMed: 20371703 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Features

The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Targets

c-Src ^[2] (Cell-free assay)	LCK ^[2] (Cell-free assay)	c-YES ^[2] (Cell-free assay)	EGFR (L861Q) ^[2] (Cell-free assay)	Lyn ^[2] (Cell-free assay)	View More
2.7 nM	<4 nM	4 nM	4 nM	5 nM	View More

In vitro

Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn, Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80 nM. Saracatinib signiﬁcantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells. ^[1] Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib shows low activity in LAPC-4, PZ-HPV7 and RWPE-1 cells. Saracatinib induces cell cycle arrest at G1/S but not caspase 3 cleavages. Saracatinib also significantly inhibits DU145 and PC3 migration in the Boyden chamber. ^[2] Saracatinib gives a potent and sustained blockage of AKT and enhances the sensitivity to irradiation in A549 and Calu-6 cells. ^[3] Saracatinib inhibits osteoclast in activity, resorption and formation. Saracatinib also reversibly prevents osteoclast precursor migration. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CTV-1	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTBwME[xOFMh\|ryP	NV\TVZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LAMA-84	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVnJR\|UxRTBwMUW5PUDPxE1?	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MEG-01	M3TQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXXnTnVSUUN3ME2wMlI{Pjh6IN88US=>	MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EM-2	NVrkPVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mm[0TWM2OD1yLkK2OUDPxE1?	NHrUW4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-15	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\jNWlEPTB;MD6yO\|QyOiEQvF2=	M1TFNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1648	NHLkfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1Ly[mlEPTB;MD6yPFEyPiEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-12	M3:0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnzhTWM2OD1yLkOyOlgh\|ryP	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LB996-RCC	NELaPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXqTWM2OD1yLkS0NVk3KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
K-562	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmL4TWM2OD1yLkS0PVY4KM7:TR?=	NF\wXGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
D-336MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFO2b3VKSzVyPUCuOVA{ODRizszN	M{TUdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NOS-1	M2fpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mlu2TWM2OD1yLk[wOVI6KM7:TR?=	MkjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EW-24	NVzFPZd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoLHTWM2OD1yLk[yOlk{KM7:TR?=	MoW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
BV-173	NIex[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1K0XmlEPTB;MD62OVI1QSEQvF2=	NHTRfoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NCCIT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{jobWlEPTB;MD63N\|IyQCEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H1436	M2G4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmX4TWM2OD1yLke5NFQ6KM7:TR?=	NWjX[WM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
BB30-HNC	M333Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXLNZoxtUUN3ME2wMlg3OjB\|IN88US=>	NIjUfIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-8	NV;XN5VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NI\ybGNKSzVyPUCuPFczPzVizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
A704	M1O5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfhW3FJUUN3ME2wMlg6OjFizszN	M17qZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TK10	NX3UWIhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jUd2lEPTB;MD65NFY3QSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KS-1	NInZXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFLTWFFKSzVyPUGuNVk4PzlizszN	NH;MfZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
C2BBe1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmnYTWM2OD1zLkKwOVA4KM7:TR?=	NUDaOWpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
RXF393	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnkWIJuUUN3ME2xMlI1OzZizszN	MoLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KGN	M4fCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEXIUmVKSzVyPUGuNlc3QDdizszN	NV:4XZA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NB69	NV\n[mUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWDJR\|UxRTFwM{e0PVch\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-11	NIP2VopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRTFwNEO0NVgh\|ryP	M2jVVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TE-1	NFLlPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkO3TWM2OD1zLkS0NVA2KM7:TR?=	NY[xT4tLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
ST486	NXe0eINHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUDY[FJZUUN3ME2xMlQ2QDV{IN88US=>	M363[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HOP-62	NVrJXI9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M37nW2lEPTB;MT61NFI1PiEQvF2=	M1rjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EW-16	M{m3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWDJR\|UxRTFwNUWwPFMh\|ryP	M4LDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LB1047-RCC	NH:ySVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NILLdJRKSzVyPUGuOVU1PTNizszN	NHXLN5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-10	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2jVcGlEPTB;MT62OlI2OiEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
RL95-2	NXzvOJZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVzIU3RQUUN3ME2xMlY3QTB{IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
DOHH-2	NYfDRm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTFwN{G3PFIh\|ryP	NULKSpF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MFH-ino	M3nrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIXh[WRKSzVyPUGuO\|c5PyEQvF2=	NU\Jd4pHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GB-1	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUfLNlI2UUN3ME2xMlc6QDN\|IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SK-N-DZ	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1nEemlEPTB;MT64OFY5QCEQvF2=	M332N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
OS-RC-2	NGG5VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4C0bmlEPTB;MT64PFU4PCEQvF2=	NFWzSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SW982	NIfpOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH;Sb5ZKSzVyPUGuPVIxQTNizszN	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KALS-1	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoDlTWM2OD1zLkm4O\|IzKM7:TR?=	M4DK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TGBC24TKB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3nmNWlEPTB;Mj6wOVk2QCEQvF2=	MlHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
GI-1	NEHlU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUTDNldKUUN3ME2yMlE3ODh2IN88US=>	NG\pbmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SW962	NUXZVYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NViwcYFuUUN3ME2yMlE4OTd6IN88US=>	M{THXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW872	M3XhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUDJR\|UxRTJwMUi1NFch\|ryP	NXnYd3QyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCI-H747	NY\xUHlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnTYTWM2OD1{LkK1O\|E1KM7:TR?=	NWOxdXJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MZ1-PC	NVPuTXJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LmbGlEPTB;Mj6yPVM2PiEQvF2=	NETIOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MSTO-211H	NWT1cnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYO1c2I6UUN3ME2yMlM2PzJ\|IN88US=>	NIjhO\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BL-70	M4nJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVXDUXoxUUN3ME2yMlQ4PDJ{IN88US=>	MojiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW954	NFPJbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4\ReWlEPTB;Mj61O\|QxQCEQvF2=	NXj2XGplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SNB75	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV;LU\|NLUUN3ME2yMlY5PTl2IN88US=>	M2n3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-SL2	NYX6dmFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4nnT2lEPTB;Mj63NlM4QSEQvF2=	NGGwUpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
GCIY	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1XVbmlEPTB;Mj64O\|AxPSEQvF2=	NE\xT\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KU812	M2LaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGX1Xm9KSzVyPUOuNFUzQTlizszN	NXjUbGdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LXF-289	M{Hj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFmyNFlKSzVyPUOuNVIyODlizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ETK-1	NV7Xd2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUO4bG1lUUN3ME2zMlIxPzZ5IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SF126	NUmzXGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVHMUlhwUUN3ME2zMlMyOTd2IN88US=>	M{PUNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LC-2-ad	NWfHT4FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NY\mbYY5UUN3ME2zMlU2PyEQvF2=	MkSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KNS-42	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPGN3VIUUN3ME2zMlY2KM7:TR?=	Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
OVCAR-4	M1rRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkXZTWM2OD1\|LkezOFM{KM7:TR?=	Mk\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
PF-382	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\EfGNpUUN3ME2zMlg{Pjl6IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SH-4	NEm4S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MU\JR\|UxRTRwMkWyOVkh\|ryP	M3fQXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
KM12	NVTMZW01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnnDTWM2OD12LkOyOFE3KM7:TR?=	M4HDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB5	M3Tz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYrOWoxUUUN3ME20MlQyQDZ2IN88US=>	NH\xOog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KURAMOCHI	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlfLTWM2OD12Lk[1NlU3KM7:TR?=	M4Hab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
Becker	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF3HNYZKSzVyPUSuOlY1OTZizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MV-4-11	M2H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUDLcYtPUUN3ME20MlgyOzR2IN88US=>	MkjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KINGS-1	NVLIZXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXvINXFEUUN3ME20MlgzOzd\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LS-123	Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MU\JR\|UxRTVwNEm2PFQh\|ryP	M{fPNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SF268	NY\0O3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYHJR\|UxRTVwNkGyOlIh\|ryP	NVPFdm4yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A388	NEPTcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTVwNkO2Olch\|ryP	NF2wSlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NMC-G1	NGrJW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlfFTWM2OD14LkCxPFEyKM7:TR?=	M1;6VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
CGTH-W-1	M2qxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1uwbGlEPTB;Nj6wNlA4PSEQvF2=	Mnz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ES4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTZwNUOwO\|Qh\|ryP	NUi1eW1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SR	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFS0W\|JKSzVyPU[uOVg5ODdizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BB49-HNC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mli5TWM2OD14LkezNlA3KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KLE	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoHzTWM2OD14Lke4N\|c4KM7:TR?=	NILScG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
HUTU-80	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHn6VZhKSzVyPU[uPVg1PjZizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SNU-C2B	NIXQ[\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV;JR\|UxRTdwOEK3N\|ch\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BB65-RCC	M3SwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MW\JR\|UxRTdwOUS5NFQh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
QIMR-WIL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnexTWM2OD16LkSyPFA5KM7:TR?=	NYXxSVZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GDM-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFnoW2RKSzVyPUiuPVczQTJizszN	NEjlNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LC4-1	NUPPXGpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWDKRlFXUUN3ME25MlAxQTFzIN88US=>	NYfZRYw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MLMA	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkTHTWM2OD17LkG1NFA3KM7:TR?=	NU\pR\|dURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EoL-1-cell	NX3hT3BMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFTocYpKSzVyPUmuN\|AyQTJizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BOKU	NX;mSodsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYHJR\|UxRTlwOU[0OlYh\|ryP	MoW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EVSA-T	M3\KV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoOwTWM2OD1zMD62OVY5KM7:TR?=	M4LldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
D-283MED	M3XGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;3[GlEPTB;MUCuPVE4PiEQvF2=	MmrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NB1	NUfGXm5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEPvUo9KSzVyPUGxMlAzPDJizszN	Mn71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
RPMI-8402	NFroXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlTnTWM2OD1zMT6xO\|gh\|ryP	NXHkc4plRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCI-H1355	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NU\4NmlUUUN3ME2xNU4yQDB4IN88US=>	NInRc4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NB7	M1n6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV\p[mxtUUN3ME2xNU4{Ojl5IN88US=>	NFHE[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
RPMI-6666	NFqyOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlrCTWM2OD1zMj65OVY4KM7:TR?=	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
697	M1LmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYfzUJc6UUN3ME2xN{4zPzBzIN88US=>	NIi2XoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
CTB-1	M4TjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnruTWM2OD1zMz61PVQ5KM7:TR?=	NVK0dYRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	NHzzfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{\BcGlEPTB;MUOuPVI{PCEQvF2=	M3r1blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BE-13	NGHCZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PZO2lEPTB;MUSuN\|kyPSEQvF2=	MkLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SKM-1	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIm2Z3hKSzVyPUG0MlQ1QTlizszN	NFXo[oM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-6	NUG0SoNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF64W29KSzVyPUG0Mlc2QTFizszN	NW[5fohHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB771-HNC	NG\o[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGrscXNKSzVyPUG0Mlc5QThizszN	M2nZWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ECC4	M{e2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NITyeGxKSzVyPUG3MlAzPzdizszN	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ES3	NF;OdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHu1bVJKSzVyPUG3MlQ3PTVizszN	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LB647-SCLC	M3\Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlXzTWM2OD1zNz60PVQ6KM7:TR?=	NI\jS\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NB10	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTkTWM2OD1zOD61NlU3KM7:TR?=	M1[zelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
L-540	NFv0WnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFXj[GpKSzVyPUG4MlgyODlizszN	M{nxb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H2126	M{P3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlrtTWM2OD1zOT61NUDPxE1?	MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HH	M3PwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M33ZeWlEPTB;MkCuNFA6QSEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MPP-89	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWrKTYUyUUN3ME2yN{4zOjh7IN88US=>	M2PpW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-MEL1	NWPOdYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlmzTWM2OD1{Mz64OlU5KM7:TR?=	NFK4RYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
KP-N-YS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXzuOoRtUUN3ME2yN{46OjV3IN88US=>	M3;CR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EC-GI-10	NInzeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M163c2lEPTB;MkSuOVk5QSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EKVX	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NInBcZVKSzVyPUK2MlAzODNizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TGBC1TKB	NES5[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4nSbmlEPTB;Mk[uOFM1KM7:TR?=	Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
Daudi	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH\LOXBKSzVyPUK3MlA4PzNizszN	MmTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ALL-PO	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmLHTWM2OD1{Nz6wPFEh\|ryP	M1rjTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB6	NWXsZ4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3PKWmlEPTB;MkeuOFg5KM7:TR?=	NGryVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ES6	NFjPNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MljjTWM2OD1{Nz65NVI{KM7:TR?=	NITDXW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
COLO-320-HSR	NXm5ZZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jqfWlEPTB;MkiuNFM4OyEQvF2=	NIr3bYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
K5	NHfDUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M33PXWlEPTB;MkiuNVI5PyEQvF2=	NVPyTmxURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
ES1	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3e2OWlEPTB;MkiuO\|c4OyEQvF2=	NILMSIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LC-1F	M{XhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTJ7LkezOFYh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SCLC-21H	NHGzXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYDVSnJKUUN3ME2zNE44OzF5IN88US=>	M376b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SK-PN-DW	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NU\ZcJhpUUN3ME2zNk42PTl6IN88US=>	NWfuUXdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
D-247MG	NWW0eXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlW5TWM2OD1\|Mj65O\|c{KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-5	M3nVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXjJR\|UxRTN\|LkCzOlIh\|ryP	NIPTW3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MONO-MAC-6	NXHwWnhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFfNVIRKSzVyPUOzMlUxPDhizszN	NV;OXVJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NFjxWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml\MTWM2OD1\|Mz63OlY3KM7:TR?=	MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LOXIMVI	NGTufGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PtNGlEPTB;M{OuO\|kzQCEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H209	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4\4W2lEPTB;M{WuNVQ1KM7:TR?=	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
A253	M4LPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXPDWYM4UUN3ME2zOU44PDJ7IN88US=>	NXXqcXI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
HCC1599	NUG2bnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWnJR\|UxRTN4LkewOVMh\|ryP	MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EB-3	NGCwU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVPYe\|UyUUN3ME2zOk46PTF6IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
GOTO	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHWxcodKSzVyPUO3MlMzOjRizszN	M3vicFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW684	M1vmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkLsTWM2OD12MT64OFk2KM7:TR?=	NFPaZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
DEL	M2fNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4rjVmlEPTB;NEKuNFUzOiEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HT-144	M1e0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIrZS2pKSzVyPUSyMlE3PzZizszN	M3nsRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TE-9	NVvWT2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoezTWM2OD12Mz60OVk3KM7:TR?=	NYDBWJFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KARPAS-45	NFjpRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUizbHZLUUN3ME20OE4{QTJ3IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HAL-01	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnvtTWM2OD12ND61NFM1KM7:TR?=	NIXVSpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
RCC10RGB	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHXFPGFKSzVyPUS0Mlc{QTJizszN	NGjDWmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
CP67-MEL	NUTYdnlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWjjcldCUUN3ME20OU43OjRzIN88US=>	M4S0PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB17	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXjnco42UUN3ME20OU43PjR\|IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SK-UT-1	M4rDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX7JR\|UxRTR3Lkm0OlQh\|ryP	MlrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
JiyoyeP-2003	NHvXSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{\BO2lEPTB;NE[uNFEyQSEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HCE-4	NHHEbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{PpZ2lEPTB;NE[uOVk3QCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H720	NHrUWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M16wSmlEPTB;NE[uO\|Y5OiEQvF2=	MkD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KARPAS-422	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGXGU5VKSzVyPUS3MlA5QTVizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	NHGzb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnjrTWM2OD12Nz6xOlIzKM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HCE-T	M3r0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn;VTWM2OD12Nz62PFI5KM7:TR?=	MkC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
PSN1	NVP6T\|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV\JR\|UxRTR5Lke4NVMh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NIH3T3	NFzLTYNHfW6ldHnvckBie3OjeR?=			NYniUlZJUW6qaXLpeIlwdiCxZjDoeY1idiClLWPyZ{BqdiCQSVizWFMh[2WubIOsJGlEPTBiPTCwMlAxOjdizszNMi=>	NWnGSGtYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOlQxPjZpPkG3NFY1ODZ4PD;hQi=>
HEK293	MVPGeY5kfGmxbjDhd5NigQ>?		Mo\ZNUBpeg>?	NVvKPY5oUW6qaXLpeIlwdiCxZjDoeY1idiCodXzsJIxmdme2aDDQT21[XDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{BGTlNiKEK0O{B1dyB{NUmgdoV{cWS3ZYOpJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gbY1ufW6xYYPhfUwhU2liPTCwMlA{QThizszNMi=>	MnLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEGxPVMoRjJ7OUSxNVk{RC:jPh?=
HEK293	NXyzPVB2TnWwY4Tpc44h[XO\|YYm=		M1e0N\|EhcHJ?	NGLIflVKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHygcIVv\3SqIGDLUXlVOSCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KHW\|aX7nJGVHWyBqMkS3JJRwKDJ3OTDy[ZNq\HWnczmgZZMhe3Wkc4TyZZRmKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDpcY12dm:jc3H5MEBKSzVyIE2gNE41OThizszNMi=>	NFXPc2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
Rh30	Mn72RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{TTOlQ5KGi{cx?=	M2TJNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUnizNEBk\WyuczDh[pRmeiB2ODDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhUUN3MDC9JFExNjFizszNMi=>	NIr3XWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4O\|A6QSd-MkO3PFcxQTl:L3G+
Huh7	M3LXN2FvfGm4aYLhcEBie3OjeR?=	M1XRfFIvPSC3TR?=	MWS1JIRigXN?	M2nySGlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDoeY1idiCKdXi3JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFUh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Huh7	NY\kPXZwSW62aY\pdoFtKGG\|c3H5	NH;kc2czNjVidV2=	MoL4OkBl[Xm\|	M4DOfWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDoeY1idiCKdXi3JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFYh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	M{XQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
Vero	MlywRY51cX[rcnHsJIF{e2G7	MUGyMlUhfU1?	M1TlfFQh\GG7cx?=	NVTYcWw1UW6qaXLpeIlwdiCxZjD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOEBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	NEXFd4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
Vero	NIPTVItCdnSrdnnyZYwh[XO\|YYm=	MnG5Nk42KHWP	MXu2JIRigXN?	M{LwbGlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IE[g[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
C6/36	NYDKdYZ1SW62aY\pdoFtKGG\|c3H5	M4nFXVIvPSC3TR?=	MXW0JIRigXN?	MlTGTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHHzbYFvKHSrZ3XyJI1we3G3aYTvJGM3NzN4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IESg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	M{jnZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
C6/36	MVHBcpRqfmm{YXygZZN{[Xl?	MXSyMlUhfU1?	NHOzS242KGSjeYO=	NViyUopmUW6qaXLpeIlwdiCxZjD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFUh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Vero	MVrBcpRqfmm{YXygZZN{[Xl?		MnjmN{Bl[Xm\|	MnXHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgSIVv\3WnII\pdpV{KGmwZnXjeIVlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[WSvaX7pd5RmemWmIHHmeIVzKH[rcnHsJINp[WyuZX7n[UBi\nSncjCzJIRigXNiYomgeolz[WxicHzhdZVmKGG\|c3H5	MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
Vero	NXz6cnpVSW62aY\pdoFtKGG\|c3H5	NWTmN3ZSOi53IIXN	M1nh[lUh\GG7cx?=	NHmzVYxKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	M33MNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
Huh7	MYTBcpRqfmm{YXygZZN{[Xl?	MWmyMlUhfU1?	NHewWmc1KGSjeYO=	Mo[wTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW\|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOEBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	NGrn[Y89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
C6/36	NYC5eJZHSW62aY\pdoFtKGG\|c3H5	NE\GUm4zNjVidV2=	NFn2Z3o3KGSjeYO=	MWnJcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYYPpZY4hfGmpZYKgcY9{eXWrdH:gR\|YwOzZiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2gZYZ1\XJiNjDkZZl{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u	NILtWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
HEK293	MUfGeY5kfGmxbjDhd5NigQ>?	MWGwMlEhfG9iMTD1US=>	NYjlTGxZOTZiaILz	MXfJcohq[mm2aX;uJI9nKGOxbHzh[4VvKElvaX7keYNm\CCGRGKyJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgNE4yKHSxIEGgeW0h[W[2ZYKgNVYhcHK\|IHL5JHdme3Sncn6gZoxwfHSrbne=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-
A673	M2PjZpFJXFNiYYPzZZk>			NHvNRo1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	M4XVU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MX\xTHRUKGG\|c3H5			NV\GXnlleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NHW2eWZyUFSVIHHzd4F6			NI\CdY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	Mk\LdWhVWyCjc4PhfS=>			NYfXS2dPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NIS4N2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NWjhdWJkeUiWUzDhd5NigQ>?			NVe3XJFJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NEKwdIVyUFSVIHHzd4F6			MlPsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NFLNOHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NWH4dI1CeUiWUzDhd5NigQ>?			NHT1PGlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NILlOHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NY[xN4QzeUiWUzDhd5NigQ>?			MlHQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MmXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NHzFS2NyUFSVIHHzd4F6			MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	M1TDV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
HEK293	NFfE[ZFHfW6ldHnvckBie3OjeR?=	MWqwMlEhfG9iMTD1US=>	MlmxNVYhcHK\|	NFrZXVNKdmirYnn0bY9vKG:oIHPvcIxi\2WwIFmtbY5lfWOnZDDESHIzKEl4M{jGJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG2IECuNUB1dyBzIIXNJIFnfGW{IEG2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p	NE\ic4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5NVM3QSd-Mk[xPVE{Pjl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pY576-FAK / pY861-FAK / FAK; PubMed: 20551056 Cancer Res (A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments. pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; PubMed: 20505783 J Cancer Sci Ther Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line. p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; PubMed: 20811583 Genes Cancer PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.	20551056 20505783 20811583
Growth inhibition assay	Cell number; PubMed: 24349321 PLoS One LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.	24349321

In vivo

Saracatinib shows great tumor growth inhibition in Src3T3 allografts and a moderate growth delay in Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. ^[1] Saracatinib shows great antitumor activity in orthotopic DU145 xenograft mice at a dose of 25mg/kg (orally administered, daily). ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase Assay: IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Speciﬁcity assays against a panel of serine/threonine kinases are performed using a ﬁlter capture assay with ³²P. Brieﬂy, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the ﬁnal concentration is approximated to the Michaelis constant (K_m). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Uniﬁlter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated.
Cell Research: ^[1]	- Collapse Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 and RWPE-1 cells Concentrations: 62.5 nM - 16 mM Incubation Time: 1, 3 and 5 days Method: Cells are seeded at a density of 2× 10³ in 96-well plates and incubated overnight. Then Saracatinib (62.5 nM-16 mM) is added to the cells. After 1, 3 and 5 days, culture medium is removed followed by addition of 0.2 mL DMSO per well and continuous shaking of plates at 200 rotations per minute for 15min. Then IC50 is measured by MTT metho (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: CB17 mice are implanted with DU145 cells. Dosages: 25 mg/kg Administration: Orally administered daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	35 mg/mL warmed (64.57 mM)
	Ethanol	31 mg/mL (57.19 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Saracatinib (AZD0530) SDF

Molecular Weight	542.03
Formula	C₂₇H₃₂ClN₅O₅
CAS No.	379231-04-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04598919	Recruiting	Drug: Saracatinab\|Drug: Placebo	Idiopathic Pulmonary Fibrosis (IPF)	National Jewish Health\|Yale University\|Icahn School of Medicine at Mount Sinai\|AstraZeneca\|National Center for Advancing Translational Science (NCATS)	November 12 2020	Phase 1\|Phase 2
NCT04307953	Recruiting	Drug: AZD0530 Difumarate\|Drug: Matching placebo	Fibrodysplasia Ossificans Progressiva	VU University Medical Center\|Royal National Orthopaedic Hospital NHS Trust\|Klinikum Garmisch-Patenkirchen\|University of Oxford\|Brigham and Women''s Hospital\|AstraZeneca\|Innovative Medicines Initiative	August 5 2020	Phase 2
NCT02085603	Completed	Drug: Saracatinib\|Drug: Placebo	Cancer	Sheffield Teaching Hospitals NHS Foundation Trust\|AstraZeneca	March 2014	Phase 2
NCT01864655	Completed	Drug: saracatinib\|Drug: Placebo	Alzheimer''s Disease	Stephen M. Strittmatter\|National Institute of Neurological Disorders and Stroke (NINDS)\|Yale University	July 2013	Phase 1
NCT01000896	Withdrawn	Drug: AZD0530\|Drug: Carboplatin\|Drug: paclitaxel	Cancer\|Non Small Cell Lung Cancer\|Epithelial Ovarian Cancer	AstraZeneca	January 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of Saracatinib?
Answer:
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Most Potent Src Inhibitor

Dasatinib : Src, IC50=0.8 nM.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Saracatinib (AZD0530)